Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) — Working Capital to Net Assets Ratio
Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) has a Working Capital to Net Assets ratio of 11.5% as of March 2026. Working capital of CN¥360.63 Million (current assets of CN¥2.49 Billion minus current liabilities of CN¥2.13 Billion) is measured against net assets of CN¥3.13 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 688076 equity to assets ratio to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Working Capital to Net Assets (2013–2025)
This chart shows how Sinopep-Allsino Biopharmaceutical Co. Ltd. A's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the ratio stands at 11.5%, reflecting working capital of CN¥360.63 Million against net assets of CN¥3.13 Billion CNY. Check how tangible is Sinopep-Allsino Biopharmaceutical Co. Lt's equity to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Sinopep-Allsino Biopharmaceutical Co. Ltd. A (2013–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Sinopep-Allsino Biopharmaceutical Co. Ltd. A from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 688076 company net worth.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 11.6% | CN¥349.12 Million | CN¥3.00 Billion | CN¥2.51 Billion | CN¥2.16 Billion | ▲ +2.2 pp |
| 2024 | 9.4% | CN¥252.82 Million | CN¥2.68 Billion | CN¥2.01 Billion | CN¥1.75 Billion | ▼ -14.4 pp |
| 2023 | 23.8% | CN¥521.43 Million | CN¥2.19 Billion | CN¥1.49 Billion | CN¥973.34 Million | ▼ -2.2 pp |
| 2022 | 26.0% | CN¥501.15 Million | CN¥1.92 Billion | CN¥1.05 Billion | CN¥551.32 Million | ▼ -19.8 pp |
| 2021 | 45.8% | CN¥828.71 Million | CN¥1.81 Billion | CN¥1.10 Billion | CN¥275.40 Million | ▲ +34.9 pp |
| 2020 | 10.9% | CN¥105.70 Million | CN¥966.02 Million | CN¥487.91 Million | CN¥382.21 Million | ▲ +15.8 pp |
| 2019 | -4.8% | CN¥-40.56 Million | CN¥838.98 Million | CN¥293.73 Million | CN¥334.30 Million | ▼ -18.5 pp |
| 2018 | 13.7% | CN¥107.63 Million | CN¥785.38 Million | CN¥357.67 Million | CN¥250.04 Million | ▲ +45.1 pp |
| 2017 | -31.4% | CN¥-100.93 Million | CN¥321.20 Million | CN¥183.31 Million | CN¥284.24 Million | ▲ +264.9 pp |
| 2016 | -296.3% | CN¥-103.57 Million | CN¥34.95 Million | CN¥21.59 Million | CN¥125.16 Million | ▼ -196.3 pp |
| 2015 | -100.0% | CN¥-73.30 Million | CN¥73.32 Million | CN¥50.06 Million | CN¥123.35 Million | ▼ -879.9 pp |
| 2014 | 779.9% | CN¥-167.46 Million | CN¥-21.47 Million | CN¥5.59 Million | CN¥173.05 Million | ▲ +4860.3 pp |
| 2013 | -4080.4% | CN¥-150.38 Million | CN¥3.69 Million | CN¥12.74 Million | CN¥163.12 Million | — |